MicroPort NeuroTech Limited (HK:2172)
:2172
Want to see HK:2172 full AI Analyst Report?
Top Page
MicroPort NeuroTech Limited
(2172)
Select Model
Select Model
Rating:65Neutral
Price Target:
HK$9.50
▼(-15.93% Downside)
Action:Reiterated
Date:05/02/26
The score is primarily supported by solid financial performance—high margins and a now-low leverage balance sheet—tempered by profit and cash-flow conversion volatility. Technical signals are notably weak (below key moving averages with negative momentum), and valuation is only moderate due to a higher P/E with limited dividend support.
Positive Factors
High Gross Margins
Sustained gross margins near 72–78% indicate durable product-level profitability and pricing power in neuromodulation. High device margins support ongoing R&D, commercialization and margin resilience versus cyclical volume swings, underpinning long-term cash generation potential.
Negative Factors
Inconsistent Cash Conversion
Irregular conversion of profits into operating cash and a year-over-year FCF decline in 2025 limit internal funding reliability. This inconsistency increases reliance on external financing for growth initiatives and makes multi-period investment planning and dividend policy less predictable.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Sustained gross margins near 72–78% indicate durable product-level profitability and pricing power in neuromodulation. High device margins support ongoing R&D, commercialization and margin resilience versus cyclical volume swings, underpinning long-term cash generation potential.
Read all positive factors
MicroPort NeuroTech Limited (2172) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.20B
Dividend Yield1.5%
Average Volume (3M)2.57M
Price to Earnings (P/E)28.6
Beta (1Y)0.86
Revenue Growth3.83%
EPS Growth-27.04%
CountryHK
Employees527
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.32
Shares Outstanding585,034,800
10 Day Avg. Volume2,683,063
30 Day Avg. Volume2,571,422
Financial Highlights & Ratios
PEG Ratio-1.07
Price to Book (P/B)3.10
Price to Sales (P/S)7.24
P/FCF Ratio36.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$12.50Price Target Upside10.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.54
Revenue Forecast (FY)HK$873.93M
MicroPort NeuroTech Limited Business Overview & Revenue Model
Company Description
Established in 2004 and headquartered in Shanghai, People's Republic of China, MicroPort NeuroTech Limited is dedicated to the research, development, manufacturing, and global commercialization of neuro-interventional medical devices. The company'...
How the Company Makes Money
MicroPort NeuroTech makes money primarily by selling neuromodulation medical devices and associated disposable/consumable components used alongside those devices. Key revenue streams typically include: (1) sales of implantable pulse generators/neu...
MicroPort NeuroTech Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
85
Very Positive
Cash Flow
67
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 770.02M | 761.76M | 665.62M | 547.35M | 382.80M |
| Gross Profit | 565.69M | 555.93M | 511.79M | 393.00M | 298.35M |
| EBITDA | 339.00M | 340.48M | 221.60M | 175.46M | 108.83M |
| Net Income | 179.73M | 254.16M | 145.55M | -21.77M | 24.17M |
Balance Sheet | |||||
| Total Assets | 2.11B | 2.04B | 1.96B | 1.82B | 1.34B |
| Cash, Cash Equivalents and Short-Term Investments | 1.02B | 1.06B | 1.00B | 1.13B | 593.29M |
| Total Debt | 15.95M | 37.12M | 61.36M | 85.24M | 109.70M |
| Total Liabilities | 315.00M | 335.70M | 322.39M | 331.35M | 1.52B |
| Stockholders Equity | 1.80B | 1.71B | 1.64B | 1.47B | -174.94M |
Cash Flow | |||||
| Free Cash Flow | 154.36M | 275.54M | -48.83M | 175.85M | 99.43M |
| Operating Cash Flow | 202.02M | 284.41M | 153.78M | 223.80M | 157.41M |
| Investing Cash Flow | -67.15M | -160.55M | -233.16M | -344.52M | -186.79M |
| Financing Cash Flow | -139.95M | -226.25M | -33.28M | 329.54M | 200.75M |
MicroPort NeuroTech Limited Technical Analysis
Positive
11.30
Price Trends
9.95
Positive
10.69
Negative
11.32
Negative
Market Momentum
0.06
Negative
67.92
Neutral
96.91
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2172, the sentiment is Positive. The current price of 11.3 is above the 20-day moving average (MA) of 9.30, above the 50-day MA of 9.95, and below the 200-day MA of 11.32, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 67.92 is Neutral, neither overbought nor oversold. The STOCH value of 96.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2172.
MicroPort NeuroTech Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$5.91B | 21.01 | 9.25% | 1.88% | 29.19% | 121.25% | |
65 Neutral | HK$6.20B | 28.61 | 10.38% | 1.50% | 3.83% | -27.04% | |
61 Neutral | HK$6.52B | 41.10 | 4.06% | ― | 5.10% | -32.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$12.67B | 28.57 | 6.07% | ― | -3.62% | ― | |
44 Neutral | HK$2.72B | -11.40 | -11.27% | ― | 16.35% | 9.84% | |
43 Neutral | HK$24.27B | -83.44 | -52.78% | ― | 114.97% | 63.21% |
* Healthcare Sector Average
HK:2172
MicroPort NeuroTech Limited
10.60
-2.28
-17.70%
HK:0853
MicroPort Scientific
6.61
-1.63
-19.78%
HK:9996
Peijia Medical Ltd.
4.04
-2.27
-35.97%
HK:1302
LifeTech Scientific Corporation
1.51
-0.48
-24.12%
HK:1858
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
8.81
-1.85
-17.33%
HK:2252
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
23.40
7.60
48.10%
MicroPort NeuroTech Limited Corporate Events
MicroPort NeuroScientific Shareholders Approve All AGM Resolutions, Including Dividend and Capital Mandates
Jun 3, 2026
MicroPort NeuroScientific Corporation reported that all ordinary resolutions proposed at its annual general meeting on June 3, 2026, were approved by shareholders via poll, including the adoption of the 2025 financial statements and the appointmen...
MicroPort NeuroScientific Expands Share Buy-Back, Citing Undervalued Stock
Jun 2, 2026
MicroPort NeuroScientific Corporation has repurchased 1,466,000 of its own shares on the Hong Kong Stock Exchange since April 28, 2026, for a total of HKD14,013,540 under a previously approved general repurchase mandate. These shares are being hel...
MicroPort NeuroScientific to Integrate BCI with Exoskeletons in OYMotion Alliance
May 28, 2026
MicroPort NeuroScientific’s Shanghai subsidiary has signed a strategic cooperation agreement with OYMotion Technologies to integrate brain-computer interface technologies with exoskeleton robot systems. The partners will combine MicroPort...
MicroPort NeuroScientific Wins FDA Clearance for Advanced NUMEN Helia Neurovascular Coil
May 25, 2026
MicroPort NeuroScientific Corporation announced that its NUMEN Helia Coil Embolization System, developed by subsidiary MicroPort NeuroTech in Shanghai, has received U.S. FDA marketing approval. This is the Group’s third coil product cleared ...
MicroPort NeuroScientific Sets 2026 AGM With Dividend and Share Buyback Mandate
May 6, 2026
MicroPort NeuroScientific Corporation has called its annual general meeting for 3 June 2026 in Shanghai, where shareholders will review the audited financial statements for the year ended 31 December 2025 and vote on board and auditor matters. The...
MicroPort NeuroScientific Sets Timetable for Proposed Final Dividend
Apr 29, 2026
MicroPort NeuroScientific Corporation has confirmed arrangements linked to a proposed final dividend for the 2025 financial year, which remains subject to shareholder approval at the annual general meeting scheduled for 3 June 2026. The move refle...
MicroPort NeuroScientific Grants 550,000 Share Options to Key Employees
Apr 1, 2026
MicroPort NeuroScientific Corporation has granted 550,000 share options to two group employees under its share scheme adopted in July 2023, with an exercise price of HK$10.97 per share and a 10-year validity period. The options will vest in equal ...
MicroPort NeuroScientific grows revenue on overseas strength despite profit hit
Mar 25, 2026
MicroPort NeuroScientific reported 2025 revenue of RMB790.5 million, up 3.8% year on year, driven mainly by strong 39.4% growth in overseas sales and expanding market share for its hemorrhagic stroke coil products. Despite this top-line progress a...
MicroPort NeuroScientific Declares HKD 0.09 Final Dividend With Scrip Option
Mar 25, 2026
MicroPort NeuroScientific Corporation has declared a final ordinary dividend of HKD 0.09 per share for the financial year ended 31 December 2025, with shareholders to approve the payout on 3 June 2026. The dividend will be paid in Hong Kong dollar...
MicroPort NeuroScientific Wins FDA Breakthrough Status for APOLLO Dream Neuro Stent
Mar 18, 2026
MicroPort NeuroScientific Corporation announced that its independently developed APOLLO Dream Rapamycin Target Eluting Stent System has received Breakthrough Device Designation from the U.S. Food and Drug Administration, the first balloon-expandab...
MicroPort NeuroScientific Sets Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 13, 2026
MicroPort NeuroScientific Corporation has scheduled a board meeting for 25 March 2026 to review and approve the group’s final results for the financial year ended 31 December 2025. The board will also consider the potential payment of a fina...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.